Project Grant K23HL183775
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $168K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $190,188 on April 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate biomarkers and predictors of treatment response in chronic anemia associated with sickle cell disease. The research evaluates the impact of anemia therapies—including hydroxyurea and blood transfusions—on cerebral tissue oxygenation and hemorheological biomarkers (blood viscosity and red blood cell...
- The National Institute of Neurological Disorders and Stroke awarded Duke University $3.119 million on September 18, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate computational and clinical tools for understanding pain variability in sickle cell disease. The funded work constitutes a prospective cohort study enrolling 1,250 individuals aged 15 years and older living with sickle cell disease in the United States. Over three years, the research...
- The National Institute of Neurological Disorders and Stroke awarded the University of Texas at Arlington $2,083,992 on September 18, 2025, to conduct longitudinal collection and computational modeling of health data in Black adolescents and young adults with sickle cell disease, with an ultimate completion date of August 31, 2030. The project, titled "Modeling Inter-Individual Differences to Address Pain of Sickle Cell Disease (MIDAS)," is supported under the Drug Use and Addiction...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $746,979 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of pain in sickle cell disease. The research uses transgenic mice with sickle cell disease to study how vaso-occlusive crises trigger severe pain. The project examines the role of lysophosphatidic acid (LPA), a pain mediator elevated during hypoxia-induced vaso-occlusion, and tests...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $171,488 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a nationwide examination of access to comprehensive care in sickle cell disease. The research uses national Medicaid insurance claims data to address two analytic aims. The first aim identifies three groups of people with sickle cell disease—those who do not receive care from a...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $834,899 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify inflammatory biosignatures that distinguish pain phenotypes in sickle cell disease. The research, titled "Inflammatory Biosignatures for the Identification of Sickle Cell Associated Pain Phenotypes (IBIS-CAP)," develops proteomic signatures composed of multiple biomarkers to characterize...
- The National Heart, Lung, and Blood Institute awarded the University of Cincinnati Sponsored Research Services Division $186,613 in project grant funding on April 10, 2026, to investigate activated microglia and cognitive deficits in adults with sickle cell disease. The research measures the density and distribution of regional and whole-brain activated microglia in 45 individuals with sickle cell disease compared to 15 healthy controls using diffusion MRI neuroimaging biomarkers. The study...
- The National Heart, Lung, and Blood Institute awarded Yale University $841,906 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 15, 2026, to conduct the SPIRIT-2 Study examining high-impact chronic pain in sickle cell disease. The study addresses three critical gaps in sickle cell disease pain management: identifying risk factors for sustained high-impact chronic pain and poor long-term outcomes; developing patient-centered endpoints to assess intervention efficacy from...
- The National Heart, Lung, and Blood Institute awarded Rutgers, The State University $165,613 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a career development project focused on improving vaso-occlusive crisis pain management for sickle cell disease in emergency departments. The award funds Dr. Melinda Rushing's development as an independent investigator in implementation science and health services research. The project proposes a...
- The National Heart Lung and Blood Institute awarded Duke University $313,416 on August 15, 2026, to validate a functional assessment tool for sickle cell disease and pilot an exercise and nutrition intervention. The award supports work under the Cardiovascular Diseases Research program (CFDA 93.837). The project will evaluate the validity and reliability of the Sickle Cell Disease Functional Assessment (SCD-FA) in a prospective cohort of adults with SCD aged 18 years and older, with the...